Form 8-K Harmony Biosciences Hold For: Apr 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Harmony Biosciences (HRMY) Enters into a License Agreement with Bioprojet
April 11, 2024 8:37 AM EDTOn April 11, 2024, Harmony Biosciences (NASDAQ: HRMY). announced that its subsidiary Harmony Biosciences, LLC (Harmony) entered into a sublicense agreement with Bioprojet Société Civile de Recherche and Bioprojet Pharma SAS (Bioprojet) for an orexin-2 receptor agonist (OX2R) (the Licensed Compound) to be evaluated for the treatment of narcolepsy and potential other indications (the Sublicense). Under the Sublicense, Harmony... More
